Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Arch Pharm Res. 2019 Nov 28;43(3):337–349. doi: 10.1007/s12272-019-01192-3

Figure 3: Induction of Nrf2-regulated quinone reductase (NQO1) activity in Hepa1c1c7 mouse hepatoma cells.

Figure 3:

There is a vast range in potency (>20,000-fold) of inducers of Nrf2 signaling used in cytoprotection studies. Optimal balance of potency, efficacy and specificity have not been defined in pre-clinical or clinical studies. Values in parentheses are the concentrations required to double NQO1 activity in Hepa1c1c7 cells. BHT, butylated hydroxytoluene; oltipraz, 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione; sulforaphane, (−)-1-isothiocyanato-(4R)-(methylsulfinyl)butane; CDDO-Im, 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Figure adapted from Kensler et al. (2010).